Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.
BioInvent International AB is a biopharmaceutical company. It develops a pipeline of innovative immuno-oncology therapies for cancer therapy based on its unique F.I.R.S.T technology platform and n-CoDeR antibody library. The products under its pipeline are BI-1206, BT-001, BI-1808, and BI-1910. Its geographical segments are Sweden, Europe, United States, Japan, and Other countries.
Lund, SE 223 70, Sweden